Poor
Partially Aligned
Patient Risk:
Low
Summary
The supplied label supports that CIALIS is tadalafil, but it does not establish U.S. marketing or availability. It provides no information about patents, exclusivity, generic availability, or launch timing, so the remaining claims cannot be verified against the label.
Category Scores
Accurate Statements
Cialis is tadalafil.
Section 11 identifies CIALIS as tadalafil.
Unsupported Statements
Cialis in the US is tadalafil.
The label identifies CIALIS as tadalafil but does not establish U.S. marketing or availability.
The core patent life for Cialis has passed.
The supplied label contains no information about patents or patent life.
Later patents covering specific Cialis formulations, dosing, or methods of use can extend legal protection and affect when generic manufacturers can launch.
The supplied label does not discuss patents, legal protection, or generic launch timing.
Multiple patents can apply to Cialis, and different patents may expire at different times.
The supplied label contains no information about patent coverage or expiration dates.
Generic tadalafil is available in the US.
The supplied label does not address generic products or U.S. availability.
The availability of generic tadalafil generally indicates that key exclusivity and patent barriers have cleared for most prescribing use cases.
The supplied label does not address generic availability, exclusivity, patents, or prescribing-use coverage.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claims concern drug identity, patents, and market availability; they do not provide dosing or safety instructions. The label cannot verify most of these claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Most claims concern patents or generic market availability, topics not addressed in the supplied label.
Suggested Improvement
Limit label-based conclusions to the identification of CIALIS as tadalafil, and clearly indicate that the supplied label does not verify U.S. availability or patent and generic-market claims.